BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Regarding the efficacy, we focused on three important indicators, early major molecular response (MMR, ≤0.1% BCR-ABL1[IS]), complete cytogenetic response (CCyR, ≤1% BCR-ABL1[IS]) and disease progression to AP-CML.